SCHEMBL2763161

SCHEMBL2763161

NC(c1ccccn1)C(O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.55
SLC6A4 P31645 2/20 0.55
SLC6A3 Q01959 1/20 0.55
SLC10A1 Q14973 2/20 0.50
KDM4E B2RXH2 2/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2C P18825 1/20 0.47
LMNA P02545 1/20 0.47
HIF1A Q16665 1/20 0.47
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.45
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
CHRM2 P08172 1/20 0.42
SCN1A P35498 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29217147 0.80 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL16781686 0.80 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3KDM4ELMNA
SCHEMBL2390921 0.78 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL29337158 0.77 CYP1A2 (0.45) SLC6A2SLC6A4SLC6A3KDM4EADRA2A
SCHEMBL23610057 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL31143646 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL31143614 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL3384423 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL477369 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E
SCHEMBL2111803 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3SLC10A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825264-B2 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them SANOFI-AVENTIS (FR) 2010-11-02 US disclosed
EP-1899320-B1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KV1 .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
US-20080188520-A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them SANOFI-AVENTIS (FR) 2008-08-07 US disclosed
EP-1899320-A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Sanofi-Aventis (FR) 2008-03-19 EP disclosed
WO-2006136305-A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI-AVENTIS (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188520-A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them KCNH1, MLLT3, CYP1A2 SLC6A2 2593/4885SLC6A4 3790/4885SLC6A3 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.